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Abstract
Background: Recombination between hepatitis C single stranded RNA viruses is a rare event.
Natural viable intragenotypic and intergenotypic recombinants between 1b-1a, 1a-1c and 2k-1b, 2i-
6p, respectively, have been reported. Diagnostically recombinants represent an intriguing challenge.
Hepatitis C genotype is defined by interrogation of the sequence composition of the 5' untranslated
region [5'UTR]. Occasionally, ambiguous specimens require further investigation of the genome,
usually by interrogation of the NS5B region. The original purpose of this study was to confirm the
existence of a suspected mixed genotype infection of genotypes 2 and 4 by clonal analysis at the
NS5B region of the genome in two specimens from two separate individuals. This initial
identification of genotype was based on analysis of the 5'UTR of the genome by reverse line probe
hybridisation [RLPH].
Results: The original diagnosis of a mixed genotype infection was not confirmed by clonal analysis
of the NS5B region of the genome. The phylogenetic analysis indicated that both specimens were
natural intergenotypic recombinant forms of HCV. The recombination was between genotypes 2k
and 1b for both specimens. The recombination break point was identified as occurring within the
NS2 region of the genome.
Conclusion: The viral recombinants identified here resemble the recombinant form originally
identified in Russia. The RLPH pattern observed in this study may be a signature indicative of this
particular type of intergenotype recombinant of hepatitis C meriting clonal analysis of NS2.
Background
Hepatitis C virus infects approximately 170 million indi-
viduals' world wide [1]. Chronicity develops in 50–80%
of infections [2,3]. Hepatitis C exists as a family of viruses,
divided into 6 genotypes each with multiple subtypes [4].
The management and treatment of chronic hepatitis C
virus [HCV] is in part guided by the genotype of the infect-
ing virus [5,6]. The requirement for liver biopsy can be
guided by genotype. Current therapeutic options of
pegylated interferon and ribavirin have a population effi-
cacy of only 50% [7]. Genotype 2 and 3 respond with effi-
cacy of 80% in clinical trials. Duration of therapy is
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genotype 1 or 4 usually have to undergo treatment for 48
weeks, while genotypes 2 and 3 usually have treatment
duration of 24 weeks. There are several methods which
can be used to determine viral genotype among which, (a)
DNA sequencing of amplicons from the 5'untranslated
region [5'UTR] (b) restriction length fragment polymor-
phism analysis and (c) Reverse Line Probe Hybridization
[RLPH] [8]. Determination of viral genotype using RLPH
can readily identify rare mixed genotype infections [9].
On occasion non-specific reactivity between probes and
amplicons can give an indication of an apparent mixed
genotype infection. However, upon repeat with addi-
tional specimens these ambiguities usually resolve to a
single genotype infection. RLPH may infrequently yield
ambiguous patterns which required further investigation.
It may be possible to discriminate between very similar
isolates by extension of the analysis to additional regions
of the genome [10]. Alternatively, there are genotype spe-
cific motifs present within NS5B which can then be used
to delineate strain genotype.
Results and Discussion
Following routine RLPH of specimen HC9A98987 it was
noticed that an unusual banding pattern indicative of a
putative genotype 2 and 4 mixed infection was evident
[Figure 1]. This interpretation is based on the fact that the
banding at positions 9, 10, and 11 are indicative of a gen-
otype 2a/c. However, a specimen of genotype 2a/c can
also have a pattern of 5, 9, 10 and 11. In addition, a band-
ing pattern of 6 and 16 is usually indicative of a genotype
4a, also, 5 and 16 is indicative of a specimen of genotype
4e. There is no banding pattern to support the existence of
a genotype 1 within this isolate. The genotype determina-
tion was repeated on several occasions for this specimen
and on an additional specimen from the same patient
(results not shown) all of which yielded the same banding
pattern. The DNA sequence analysis of the 5'UTR indi-
cated that the specimen was of genotype 2, GenBank
[DQ417427], with no definable subtype or indication of
a mixed genotype infection with a strain of genotype 4. In
light of this fact, clonal analysis of the NS5B region from
HC9A98987 was undertaken. 14 clones were sequenced
[DQ417439–DQ417452]. A search for similarities with
previously published sequences was performed with the
program Blast. [11] The results indicated that this region
of the genome had homology to sequences of HCV 1b
[e.g., D50485, AF31916] and not the expected genotype 2
or 4. The corresponding amino acid sequences analysis
indicated that there were only 7 unique isolates, GenBank
[DQ417439, DQ417443, DQ417446, DQ417447,
DQ417449, DQ417451, DQ417452].
Subsequent clonal analysis of (i) the core sequences
[DQ417428–DQ417433] and (ii) the HVR1 sequences
The 5'UTR amplicon used in the RLPH assay was generated using the oche Diagnostics COBAS AMPLICOR HCV MONITOR kitFigure 1
The 5'UTR amplicon used in the RLPH assay was generated 
using the Roche Diagnostics COBAS AMPLICOR HCV 
MONITOR kit. Hybridization and subsequent chromogenic 
development were performed as per AutoLipa-Versant pro-
tocol. Lane 1, HC9A98987; Lane 2, negative control; M, 
Interpretation chart; CONJ CTRL, conjugate control; AMP 
CTRL, PCR amplification control. The HCV specific banding 
pattern observed was 5, 6 (weak), 9–11, 16. A banding pat-
tern of 5, 9–11 is indicative of a genotype 2a/2c infection, 
while banding at positions 6 and 16 are usually indicative of a 
genotype 4a infection and banding at positions 5 and 16 can 
be indicative of a genotype 4e. The nitrocellulose strip most 
proximal to the interpretation chart is the negative control.Page 2 of 7
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the genome were in fact homologous to viruses within the
2k subtype [e.g., AB031663]. Two clones from the core
region had synonymous mutations [DQ417430,
DQ417433]. The HCV 2k [e.g., AB031663] isolate has a
relatively high prevalence in the countries of the former
USSR. Kalinina et al reported in 2002 the identification of
a natural intergenotypic recombinant form of HCV which
had homology to 2k at the 5' end of the genome and to 1b
at the 3' end of the genome [12]. The cross over point was
identified as occurring within the NS2 region by Simplot
by Kalinina [12].
Following these observations, the core, the HVR1 and the
NS5B amino acid sequences from HC9A98987 were
aligned against reference strains of different genotypes
[AY587845 (2k/1b), AB031663 (2k), AF313916 (1b) and
D50485 (1b)] and a phylogenetic analysis was carried
out. Phylogenetic trees were constructed with the NEIGH-
BOR program in the PHYLIP package and genetic dis-
tances were calculated with PRODIST program in the
PHYLIP package based on Kimura's distance. [13] The
results indicated clearly that sequences corresponding to
specimen HC9A98987 are related to genotype 2k in the
core and HVR1 region (data not shown) and closely
related to genotype 1b in the NS5B region [Figure 2]. All
of these three regions are highly homologous with
AY587845 (2k/1b) the recombinant form initially identi-
fied in Russia [12].
To investigate if specimen HC9A98987 was a possible
recombinant form of HCV, primers were designed with
the Primer3 program [14] to span the previously identi-
fied recombination point. A product of the expected 346
Phylogenetic tree generated by NEIGHBOR program in the PHYLIP package for NS5B and core amino acid sequencesFigure 2
Phylogenetic tree generated by NEIGHBOR program in the PHYLIP package for NS5B and core amino acid sequences. Genetic 
distance was calculated with PRODIST program from the PHYLIP package based on Kimura's distance. A bootstrap analysis 
using 100 bootstrap replicates was performed to assess the reliability of each branch point. Bootstrap values greater than 70% 
are shown. The corresponding genetic distances are also shown. The arc signifies the sequences generated from HC9A98987. 
The dashed line reflects a genetic distance of 0.29 between AY587845 (2k/1b) and AB031663 (2k).
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was recovered by nested RT-PCR [Table 1]. The amplicon
was cloned and the DNA sequence from 5 clones exam-
ined. Four of the 5 clones were found to be identical at the
level of amino acid sequence [DQ839386–DQ839389]
with a minor quasispecies [DQ839390]. Sequence analy-
sis indicated that this region of specimen HC9A98987 is
homologous with the reference strain [AY587845] [Figure
3]. The recombinant form identified here likely shares the
same cross over point as the RF_2k/1b reported by
Kalinina [12]. This is the first independent identification
of this natural intergenotypic recombinant of HCV
between 2k/1b.
Following the identification of HC9A98987 as a recom-
binant form of HCV similar to AY587845 (2k/1b), the
laboratory investigated whether an additional specimen
(hence, HC9A99966) from another individual with the
same RLPH pattern was also a candidate natural intergen-
otypic recombinant form. Clonal analysis of the NS2
region was performed on this specimen from the second
patient (HC9A99966). The sequences of six clones were
determined. All six clones were of identical nucleotide
sequence [DQ904446] and were found by sequence anal-
ysis to be homologous to the natural intergenotypic
recombinant related to HC9A98987, i.e., AY587845 (2k/
1b) [Figure 3].
While, the prevalence of the 2k/1b recombinant form of
HCV is globally low, its existence poses an interesting
challenge as to what anti-viral regimen should be fol-
lowed. Mechanistically the identification of a recom-
binant strain of HCV, a single stranded RNA virus, poses
some interesting questions. The initial recombination
event had to happen in a hepatocyte infected with a 2k
and a 1b isolate. Recombination had to maintain the
reading frame of the polyprotein. The majority of recom-
bination events would be expected to yield fatal nucle-
otide lesions generating life cycle incompetent virions. It
is interesting to hypothesize that perhaps the generation
of this recombinant form of HCV is the result of "strand
switching" during replication rather than classical recom-
bination-ligation of viral RNA as previously proposed
[15].
An additional natural intergenotypic recombinant
between genotypes 2i and 6p has very recently been
described [16]. The recombination break point was again
narrowed down to a region at the 3' end of the NS2 gene,
possibly extending into the NS3 gene. It is currently evi-
dent that the viable recombination occurs infrequently in
HCV biology. The frequency of this phenomenon may be
under estimated. In an attempt to estimate the prevalence
of HCV recombinants Cristina and Colina recently
reported the identification of an intragenotypic recom-
binant between 1a and 1c by examining only 89 full
length sequences, representative of all genotypes present
in the LANL database [17,18]. These results may give an
insight into the actual prevalence of HCV recombinant
forms but would require prospective examination to ver-
ify the findings. Molecular characterisation of these natu-
ral chimeras may yet yield some unique insights into life
cycle of hepatitis C. Recombinant forms for HIV do not
have the same sensitivity to anti-retroviral therapy as wild
type HIV-1 clade B isolates [19]. The sensitivity of recom-
binant forms of HCV to pegylated interferon based ther-
apy is unknown. Intergenotypic recombinant isolates that
have genotype 1 as part of the genomic backbone will
likely require a conservative approach, with patients being
treated for 48 rather than 24 weeks.
Conclusion
The diagnostic standard for determining HCV genotype,
irrespective of methodology, is to interrogate the
sequence of the 5'UTR. The serendipitous identification of
two recombinant forms of HCV, related to the Russian 2k/
Table 1: Primer details for the amplification of core and NS2
Region Polarity Primer sequence
Corea Positionb
Core A1 Sense 5'-GAGTGCCCCGGGAGGTCTCGTAGA-3' 309–332
Core A2 Antisense 5'-RCCRCAYGTRANGGTRTCGATGAC-3' 705–728
Core B1 Antisense 5'-GCRAARCCRCAYGTRANGGTRTCG-3' 710–733
Core B2 Sense 5'-GGGAGGTCTCGTAGACCGTGCA-3' 318–339
NS2 Positionc
NS2 KOS Sense 5'-GCAAGCTCTGTTGAGGATAT-3' 3025–3044
NS2 KOAS Antisense 5'-TGTGAGGCTAGTGACGATGC-3' 3405–3424
NS2 KIS Sense 5'-GGTGGCAAGTACGTCCAGAT-3' 3068–3087
NS2 KIAS Antisense 5'-TGACGATGCAGCCAAGTAAG-3' 3394–3413
a Y = C or T; R = A or G; N = A, T, G or C.
b Reference strain NC_004102 (1a)
c Reference strain AY587845 (2k/1b)Page 4 of 7
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detailed molecular investigation across the genome. The
RLPH pattern observed in this study may be a signature
indicative of this particular type of intergenotype recom-
binant of hepatitis C meriting clonal analysis of NS2. Per-
haps diagnostic laboratories need to consider
confirmation of genotype by interrogation of the NS5B to
ensure that management of chronic HCV is optimal.
Methods
HCV Genotyping
The specimens referred to in this manuscript were
received as part of the routine diagnostic services provided
by the Molecular Virology Diagnostic and Research Labo-
ratory to Cork University Hospital. The viral status of all
specimens received by the diagnostic laboratory are qual-
itatively and quantitatively evaluated. Subsequent to con-
firmation of viraemia, specimens are routinely genotyped
by RLPH (Versant-Bayer, UK) [20]. The specimens used
during the study outlined here are HC9A98987 and
HC9A99966, each from separate unrelated individuals
originally from Russia and Georgia, respectively, but resi-
dent in Ireland at the time of sample acquisition.
RT-PCR
The RNA (QIAGEN, UK. Qiamp viral RNA) was randomly
primed to generate cDNA with AMV reverse transcriptase
(Promega, USA). Taq DNA polymerase (Promega, USA)
was used to amplify the core, HVR1 and NS5B amplicons.
Pwo DNA polymerase (Roche, UK) was used to amplify
the NS2 amplicon. The primers used to amplify the core
and the NS2 regions are listed in Table 1. The primers used
to amplify the HVR1 region were described by Farci et al
[21]. The core, the HVR1 and the NS2 primary and sec-
ondary PCRs were carried out under the following condi-
tions: 94°C for 3 min., 35 cycles of 94°C for 15 s, 60°C
(core), 62°C (HVR1) 55°C (primary PCR NS2) or 58°C
(secondary PCR NS2) for 30 s and elongation at 72°C for
45 s; a final elongation at 72°C for 10 min. completed the
PCR. To amplify the NS5B region, a hemi-nested PCR was
Amino acid alignment of sequences from sera (a) HC9A98987 [DQ839386, DQ839390] and (b) HC9A99966 [DQ904446], and reference strain [AB031663] (2k), [AY587845] (2k/1b), [D50485] (1b) and [AF313916] (1 from the NS2 regionFigure 3
Amino acid alignment of sequences from sera (a) HC9A98987 [DQ839386, DQ839390] and (b) HC9A99966 [DQ904446], 
and reference strain [AB031663] (2k), [AY587845] (2k/1b), [D50485] (1b) and [AF313916] (1b) from the NS2 region. The 
recombination break point as identified by Kalinina is marked by the arrowhead. The directionality of the genotypes is indi-
cated by the arrow, with subscripted genotype/subtype.
                  1                                                50 
AB031663  GGKYVQMMLLTLGKWTGTYIYDHLSPMSGWAASGLRDLAVAVEPIVFSPM 
AY587845  -------------R----------T-LQD—-HA-----------V---D- 
DQ839386  -------V----------------T-LRD—-HE-----------V---D- 
DQ839390  -------A----------------T-LRD—-HA-----------V---D- 
DQ904446  -------------R----------T-LRD--HE-----------V---D- 
D50485  --H----AFMK-AAL----V----T-LQD—-HA-----------V---D- 
AF31916  --H----A-MR-AAL----V----T-LRD—-HE-----------V---D- 
 
 
                 51                                                100 
AB031663  EKKVIVWGAETAACGDILHGLPVSARLGQEVLLGPADEYTSKGWKLLAPI 
AY587845  -T-I-T-----------IL-------R-R-I------SLEGQ—-R----- 
DQ839386  -T-I-T---D-------IL-------R-R-I------SFEGQ--R----- 
DQ839390  -T-I-T---D-------IL-------R-R-I------SFEGQ—-R----- 
DQ904446  -T-I-T---D-------IL-------K-R-IF-----SLEGQ--R----- 
D50485  -T-I-T---D-------IL--A----R-K-IF-----SLEGS—-R----- 
AF31916  -T-I-T---D-------IL-------R-R-I------SLEGQ—-R----- 
 
                 101            115 
AB031663  TAYAQQTRGLLGTIV 
AY587845  ---S--------C-- 
DQ839386  ---S--------C-- 
DQ839390  ---S--------C-- 
DQ904446  ---S--------C-- 
D50485  ---S--------C-I 
AF31916  ---A--------C-- 
1b2kPage 5 of 7
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Morice et al and Pr5 designed by Sandres-Saune et al under
the following PCR conditions: 95°C for 5 min., 35 cycles
of 95°C for 30 s, 58°C (primary PCR with Pr3 and Pr4) or
55°C (secondary PCR with Pr3 and Pr5) for 30 s and elon-
gation at 72°C for 30 s; a final elongation at 72°C for 10
min. completed the PCR [22,23]. 5'UTR sequence was
determined following amplification of the region from
position -299 to 6nt (based on prototype strain
M632321).
Clonal Analysis
The Taq DNA polymerase generated amplicons were
cloned into DH5α by TA cloning (Invitrogen Belgium).
The NS2 amplicon was cloned by use of the Zero Blunt
TOPO system (Invitrogen, Belgium). DNA sequencing
was out sourced to MWG, Germany.
Sequence similarities between the sequences generated
during this study were examined by use of the BLASTN
web program [11]. Sequence alignment was performed
with CLUSTALW (version 1.74) [24]. Phylogenetic analy-
ses were conducted by using the NEIGHBOR program in
the PHYLIP package [13]. A boostrap analysis using 100
bootstrap replicates was tested. Genetic distances were cal-
culated with PRODIST from the PHYLIP package based on
Kimura's distance.
Reference strains used in the present study were all
obtained from GenBank [AY587845 (genotype 2k/1b),
AB031663 (genotype 2k), D50485 (genotype 1b) and
AF31916 (genotype 1b)]. Nucleotide sequences reported
in this study have been assigned the following accession
numbers which were derived from HC9A98987 Genbank:
[DQ417427] (5'UTR). [DQ417428 to DQ417433] (Core
sequences), [DQ417434 to DQ417438] (HVR1
sequences), [DQ417439 to DQ417452] (NS5B
sequences), [DQ839386 to DQ839390] (NS2 sequences).
[DQ904446] was derived from the NS2 sequence from
sera HC9A99966.
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